Rafael Arroyo1, Carlos Vila, Steve Clissold. 1. Neurology Service, Hospital Clínico San Carlos, C/ Martin Lago s/n 28040 Madrid, Spain. rafarro@terra.es
Abstract
BACKGROUND: Multiple sclerosis spasticity (MSS) is a common and disabling symptom for which a number of antispastic agents are available; however, evidence-based guidelines for optimal management are lacking. OBJECTIVE: This retrospective observational assessment investigated the current management approach for resistant MSS in Spain. Secondary objectives were to evaluate the evolution of MSS and to estimate the social and health-related costs of managing MSS in the Spanish healthcare system. METHODS: A retrospective analysis was performed using case records from 212 MS patients with spasticity that were resistant to ≥ 1 previous therapy. Data were collected over 1-3 years (mean 2.1 years), including: sociodemographics, medical history, clinical scores and all therapy/other resources consumed (e.g., rehabilitation and carers' time). Disease progression was estimated from the evolution of recorded clinical scales, and an analysis of costs from a Spanish healthcare and social perspective was performed. RESULTS: The majority of patients were female and most had secondary progressive MS. Baclofen (76-80%), tizanidine and benzodiazepines were the most common antispastic drugs administered. A variety of spasticity rating scales were employed, and they demonstrated the same general trends. MS progressed, with the composite score for spasticity and mobility deteriorating in 46.4% of patients, and there were no marked differences between antispasticity drugs. The annual healthcare-related cost of treating an MSS resistant patient in the Spanish healthcare system was €15,405, largely attributable to the cost of disease-modifying drugs and care provision. Other aspects, such as medical visits and antispastic treatments, formed only a small portion of cost. CONCLUSIONS: MSS progresses despite treatment with currently available antispastic agents, and it is associated with a high level of disability. Spasticity treatment represents a minor element of the overall cost of managing MSS patients in Spain. The approach to the assessment of spasticity varies between centers.
BACKGROUND:Multiple sclerosis spasticity (MSS) is a common and disabling symptom for which a number of antispastic agents are available; however, evidence-based guidelines for optimal management are lacking. OBJECTIVE: This retrospective observational assessment investigated the current management approach for resistant MSS in Spain. Secondary objectives were to evaluate the evolution of MSS and to estimate the social and health-related costs of managing MSS in the Spanish healthcare system. METHODS: A retrospective analysis was performed using case records from 212 MS patients with spasticity that were resistant to ≥ 1 previous therapy. Data were collected over 1-3 years (mean 2.1 years), including: sociodemographics, medical history, clinical scores and all therapy/other resources consumed (e.g., rehabilitation and carers' time). Disease progression was estimated from the evolution of recorded clinical scales, and an analysis of costs from a Spanish healthcare and social perspective was performed. RESULTS: The majority of patients were female and most had secondary progressive MS. Baclofen (76-80%), tizanidine and benzodiazepines were the most common antispastic drugs administered. A variety of spasticity rating scales were employed, and they demonstrated the same general trends. MS progressed, with the composite score for spasticity and mobility deteriorating in 46.4% of patients, and there were no marked differences between antispasticity drugs. The annual healthcare-related cost of treating an MSS resistant patient in the Spanish healthcare system was €15,405, largely attributable to the cost of disease-modifying drugs and care provision. Other aspects, such as medical visits and antispastic treatments, formed only a small portion of cost. CONCLUSIONS:MSS progresses despite treatment with currently available antispastic agents, and it is associated with a high level of disability. Spasticity treatment represents a minor element of the overall cost of managing MSSpatients in Spain. The approach to the assessment of spasticity varies between centers.
Authors: Joanne M Wagner; Theodore R Kremer; Linda R Van Dillen; Robert T Naismith Journal: Arch Phys Med Rehabil Date: 2014-02-28 Impact factor: 3.966
Authors: Samuel Herzog; Marian Shanahan; Peter Grimison; Anh Tran; Nicole Wong; Nicholas Lintzeris; John Simes; Martin Stockler; Rachael L Morton Journal: Pharmacoeconomics Date: 2018-01 Impact factor: 4.981
Authors: Oleguer Parés-Badell; Gabriela Barbaglia; Petra Jerinic; Anders Gustavsson; Luis Salvador-Carulla; Jordi Alonso Journal: PLoS One Date: 2014-08-18 Impact factor: 3.240
Authors: Thomas Henze; Sylvia von Mackensen; Gerald Lehrieder; Uwe K Zettl; Carmen Pfiffner; Peter Flachenecker Journal: Health Qual Life Outcomes Date: 2014-08-01 Impact factor: 3.186